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ABSTRACT
Significant advances have been achieved in recent years in the identification of 
the genetic and the molecular alterations of pancreatic ductal adenocarcinoma (PDAC). 
Despite this, at present the understanding of the precise mechanisms involved in the 
development and malignant transformation of PDAC remain relatively limited. Here, 
we evaluated for the first time, the molecular heterogeneity of PDAC tumors, through 
simultaneous assessment of the gene expression profile (GEP) for both coding and 
non-coding genes of tumor samples from 27 consecutive PDAC patients. Overall, 
we identified a common GEP for all PDAC tumors, characterized by an increased 
expression of genes involved in PDAC cell proliferation, local invasion and metastatic 
capacity, together with a significant alteration of the early steps of the cellular 
immune response. At the same time, we confirm and extend on previous observations 
about the genetic complexity of PDAC tumors as revealed by the demonstration of 
two clearly distinct and unique GEPs (e.g. epithelial-like vs. mesenchymal-like) 
reflecting the alteration of different signaling pathways involved in the oncogenesis 
and progression of these tumors. Our results also highlight the potential role of the 
immune system microenvironment in these tumors, with potential diagnostic and 
therapeutic implications.
INTRODUCTION
In recent years, important advances have been 
achieved in the identification of the genetic and molecular 
alterations of pancreatic ductal adenocarcinoma (PDAC). 
Such studies have also shown that PDAC is a genetically 
highly-heterogeneous and complex group of tumors [1-6]. 
However, the knowledge about the precise mechanisms 
underlying the development and malignant transformation 
of PDAC, still remain largely unknown. In this regard, 
global gene expression profiling (GEP) at both the mRNA 
and the protein levels has proven to allow identification of 
distinct molecular tumor subtypes in many different human 
cancer types [7-9]. In recent years, many GEP studies have 
been also reported in PDAC [4, 10-24]; such studies, have 
mainly focused on the definition of molecular signatures 
associated with disease progression; but, to the best of our 
knowledge, only Collisson et al. [25] described (three) 
PDAC subtypes based on microarray analysis of GEP 
which were associated with different clinical outcomes and 
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therapeutic responses: the classical, quasi-mesenchymal 
and exocrine-like subtypes of PDAC tumors. Currently, it 
is well-established that the cellular mechanisms involved 
in tumor genesis and progression depend, not only on the 
protein-coding GEP, but also on the expression profile of 
post-transcriptional regulators such as the miRNAs. Thus, 
simultaneous assessment of the mRNA and the non-coding 
RNA gene expression profiles may contribute to a better 
understanding of the molecular pathways of PDAC and a 
more accurate definition of the distinct molecular subtypes 
of these tumors. To date, only a few studies by Donahue 
et al. [26] and Frampton et al. [27] have combined global 
mRNA and miRNA expression analysis of PDAC tumors. 
In the former study, combined GEP data and DNA copy 
number alterations were investigated in a cohort of 25 
primary PDAC tumors in an attempt to identify tumoral 
molecular profiles associated with a distinct patient 
survival. By contrast, Frampton et al. [27] analysed the 
impact of miRNA expression on the whole mRNA GEP 
in a small cohort of PDAC tumors (n = 9) and cell lines 
(n = 2) aiming at the identification of functional miRNA-
mRNA interactions that could contribute to PDAC growth. 
 Here we evaluate the molecular heterogeneity 
of PDAC tumors based on simultaneous assessment of 
the overall GEP of both coding mRNA and non-coding 
RNA genes -including miRNA, small nucleolar and large 
intergenic RNAs- in primary tumor samples from 27 
consecutive PDAC patients vs. non-tumoral pancreatic 
tissue. Overall, our results define a common GEP for all 
PDAC tumors, at the same time they confirm and extend 
on previous observations about the existence of two 
clearly distinct molecular subtypes of PDAC.
RESULTS
The global transcription profile of PDAC tumors
Supervised analysis of the PDAC GEP showed a 
total of 1,428 mRNA and 171 small RNA deregulated 
genes, with an average expression level ≥ 2-fold difference 
in PDAC tumors (n = 27) vs. non-PDAC pancreatic 
tissues (n = 5) (FDR < .0001; Supplementary Tables 2 
and 3). More than half of these mRNA transcripts were 
up-regulated in PDAC samples (923/1428; 64%) while 
most small RNA transcripts (135/171; 78%) were down-
regulated in PDAC samples. Among other genes, POSTN, 
SULF1, GREM1 and DKK1 mRNAs and the miR-203, 
miR-708, miR-31 and miR-4298 miRNA transcripts were 
those found to be overexpressed at the greatest levels, 
while the ALB, PDIA2, SYNCN, RBPJL mRNAs and the 
miR-216-a and miR-216-b, miR-217, miR-148a and miR-
4286 miRNAs were those showing the most pronounced 
down-regulation across all PDAC samples analyzed (Table 
1). ROC curve analysis based on those mRNA and miRNA 
transcripts differentially expressed in PDAC vs. non-
tumoral pancreatic tissues, revealed a combination of just 
5 genes (S100A11, GPR137B, SULF1, POSTN and miR-
155) that allowed accurate classification (32/32 samples 
correctly classified) of PDAC tumor vs. non-tumoral 
pancreatic tissues (Table 2). 
The gene expression profiling of PDAC vs. non-
tumoral pancreatic tissues defines two molecular 
subgroups of PDAC tumors
Despite there were global differences in the GEP 
of PDAC vs. non-tumoral pancreatic tissues (Table 1; 
Supplementary Tables 2 and 3), both unsupervised PCA 
(Figure 1A) and HCA (Figure 1B), showed two well-
defined subgroups of PDAC tumor samples with distinct 
GEP: 1) a major group consisting of 24/27 PDAC samples 
(GEP-A subgroup of tumors) and 2) a minor subgroup 
of three PDAC tumors which clustered together, clearly 
apart from the GEP-A PDAC tumors (GEP-B subgroup of 
PDAC). Of note both the GEP-A and GEP-B subgroups 
of PDAC tumors also clustered separately from the non-
tumoral pancreatic tissue samples (n = 5; Figure 1). 
Taking in account these GEP-based subgroups of 
PDAC tumors, supervised analysis showed a total of 2,594 
mRNA and 214 small RNA altered genes among GEP-A 
and GEP-B tumors vs. non-tumoral pancreatic tissue 
samples (Table 1; Supplementary Tables 2 and 3). Upon 
comparing the GEP of the GEP-A and GEP-B subgroups 
of PDAC tumors: 1,605/2,594 (62%) and 181/214 (85%) 
differentially expressed mRNA and small RNA genes 
were associated with the GEP-A cluster, respectively, 
while 1,522/2,594 (59%) and 103/214 (48%) mRNA 
and small RNA genes were associated with the GEP-B 
cluster, respectively; a total of 533 (21%) mRNA and 70 
(33%) small RNA transcripts were simultaneously altered 
in the two subgroups of PDAC tumors (Supplementary 
Tables 2 and 3). The altered gene profile common to the 
GEP-A and GEP-B tumors included increased expression 
of mRNA coding for the RAC1 and RHOC GTP-binding 
proteins, the insulin-like growth factor binding protein 3 
(IGFBP3), several members of the S100A and the MMP 
gene families (e.g.: S100A6, 11 and 16, and MMP2, 11 
and 14), as well as the PDAC-associated miRNAs miR-
155 and miR-203, which are known to be typically altered 
in PDAC; in addition, both subgroups of PDAC tumors 
also showed loss of expression of normal pancreatic 
genes such as the CELA2A (pancreatic elastase), 
the CEL, PNLIP, PNLIPRP1 and PNLIPRP2 genes 
(pancreatic lipases and related proteins), the SERPINI2 
serin peptidase inhibitor gene and the miR-216, miR-217 
and miR-148 miRNAs. In turn, those genes which were 
found to be differentially altered in the GEP-A and GEP-B 
tumor subgroups, included, among other, the KRAS 
oncogene, the CEACAM1 and CEACAM5 epithelial 
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marker carcinoembrionary antigens, the SERPINB5 gene, 
as well as the miR-21, miR-221 and miR-222 miRNAs 
which were all overexpressed in GEP-A vs. GEP-B tumors 
(Supplementary Tables 2 and 3). 
Supervised analysis further showed differential 
expression for another 20 genes in GEP-A vs. GEP-B 
PDAC tumors (Supplementary Table 2). Among other 
altered genes, these included greater expression in GEP-A 
(vs. GEP-B) PDAC of the CEACAM6 gene, as well as 
of genes associated with the inflammatory response 
and chronic pancreatic diseases such as the integrin 
β4 and β6 genes (ITGB4 and ITGB6), the cytochrome 
b-245 beta polypeptide (CYBB), lysozyme (LZY), the 
SERPINA1 antiproteinase and the antitrypsin serpin 
peptidase inhibitor genes, together with genes involved 
in tumor metastasis and invasion –e.g. the MMP7 matrix 
metalloproteinase and the tetraspanin 8 (TSPAN8) genes- 
(Supplementary Table 2).
Functional characterization of deregulated GEP 
in PDAC tumors
Analysis of the biological and functional significance 
of the deregulated GEPs observed in our PDAC tumors, 
revealed > 55 significantly altered canonical pathways vs. 
non-tumoral pancreatic tissues. Among those pathways 
more commonly altered in PDAC tumors we observed 
increased expression of genes involved in axonal 
guidance, the actin cytoskeleton and/or endocytosis 
processes such as integrins (TGA5, ITGB1), GTP-ases 
(RRAS and RAC1) and actin-related proteins (ACTR3); 
in addition, genes that participate in the early steps of 
inflammatory cell responses, such as genes associated with 
leukocyte extravasation, cell adhesion and diapedesis, and 
with IL-8 signaling, together with genes involved in cell 
motility, were altered in tumoral tissues from both groups 
of PDAC, as reflected by an increased expression of the 
Figure 1: Classification of PDAC tumors and non-tumoral pancreatic tissues based on coding (mRNA) and non-
coding (small nuclear and microRNA) gene expression profiles (GEP). Both principal component (Panel A) and unsupervised 
hierarchical clustering (Panel B) analyses differentiated tumoral vs. non-tumoral tissues (n = 5; color coded in green), at the same time they 
showed the existence of two major subgroups of PDAC tumors: GEP group A (n = 24; color coded in red) and GEP group B (n = 3; color 
coded in purple). Case ID of tumors are shown inside the colored bars.
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Figure 2: Most representative canonical pathways involved in PDAC tumors as defined by their GEP for both coding 
and non-coding RNAs (n = 27; p < .05). Shared canonical pathways by the two GEP-A and GEP-B subgroups of PDAC tumors are 
shown in panel A, while those pathways specific for the GEP-A and GEP-B subgroups of PDAC tumors are displayed in panels B and C, 
respectively. 
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MMP2, MMP11 and MMP14 matrix metalloproteinases 
and the MSN (moesin), CDH11 (cadherin 11), RHOC 
(Ras homolog C) and CFL1 (cofilin 1) genes, in parallel 
to a decreased expression of the CLDN3 (claudin 3) gene 
(Figure 2A; Supplementary Table 4). Both subgroups 
of tumors also displayed increased expression of genes 
involved in bladder cancer signaling pathways and glioma 
invasiveness (Figure 2).
Functional characterization of GEP differentially 
altered in GEP-A and GEP-B PDAC
Canonical pathways found to be deregulated in 
GEP-A vs. GEP-B PDAC (Figure 2B and 2C) included 
multiple genes involved in innate and adaptive cellular and 
humoral immune responses. Among others, these included 
interleukin 18 (IL18), several IL receptors (IL2RA, 
IL2RG, IL10RA) and the IL1RN IL-1 antagonist, the 
CD80 receptor gene, major histocompatibility complex 
class I (HLA-A, HLA-B, HLA-E and HLA-F) and 
class II (HLA-DRA, HLA-DMA, HLA-DMB, HLA-
DPA1 and -DQB1) molecules, toll-like receptors 4 and 
6 (TLR-4 and TLR-6) and both the janus kinase family 
members 1 and 2 genes (JAK1 and JAK2) and their 
signal transducer and activator of transcription 2 gene 
(STAT2). In contrast to GEP-B cases, GEP-A tumors also 
displayed an altered expression of genes involved in cell 
stress, injury responses and chronic inflammatory disease 
pathways; this included overexpression of the COL3A1 
and COL10A1 collagen genes, the PLA2G7, 10 and 16 
phospholipases, the APOL1 and APOC1 apolipoproteins 
and the PLAT and PLAU plasminogen activator-
associated kinase genes (Figure 2B and Supplementary 
Table 5). Conversely, GEP-B tumors displayed a less 
altered GEP, which consisted of decreased expression of 
genes related with cell junction and intercellular adhesion 
-e.g. the E-cadherin (CDH1), OCLN (occludin) and CGN 
(cingulin) genes, and several members of the claudin 
gene family (CLDN1, CLDN4, CLDN7 and CLDN10)- 
together with increased expression of the ILK signaling 
pathway, due to overexpression of the ILK gene and of 
other genes involved in the ephitelial-to-mesenchymal 
transition (EMT) such as SNAI1, SNAI2 and vimentin 
(VIM) (Figure 2C and Supplementary Table 6). Of note, 
GEP-B tumors also showed a GEP which was associated 
with other key elements of the GEP signature of EMT; 
thus, they showed overexpression of the N-cadherin 
(CDH2), TWIST1 and S100A4 mesenchymal phenotype-
associated markers, together with decreased expression 
of epithelial phenotype markers such as the CDH1, 
cytokeratins (KRT8 and KRT18), desmoplakin (DSP), the 
chymotrypsinogen B1 (CTRB1), insulin (INS) and GCG 
genes.
From all differentially expressed RNA transcripts, 
a combination of 63 mRNA genes overexpressed in 
GEP-A and 97 mRNA genes overexpressed in GEP-B 
tumors (vs. non-tumoral pancreatic tissues) allowed 
for a clear cut discrimination of these two subgroups of 
PDAC tumors (Supplementary Table 7). A list of those 
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highly-discriminant genes which were found to be most 
differentially expressed (≥10 fold difference) in GEP-A 
and GEP-B tumors, with a power to classify them with 
a 100% accuracy, are shown in Table 3. These genes 
included PDAC epithelial markers (e.g., CEACAM5 and 
SERPINB5) for the definition of GEP-A tumors and the 
SNAI2 mesenchymal marker for GEP-B tumors. 
Validation of tumor-associated markers with high 
discriminating power between the GEP-A vs. 
GEP-B subgroups of PDAC
The discriminating value of those genes 
differentially expressed (overexpressed) in GEP-A vs. 
GEP-B PDAC tumors (Supplementary Table 7) was 
further validated using GEP data from an independent 
series of PDAC available at the public GEO database (n 
= 27; Figure 3). In line with the findings described above 
for our cases, 14/14 (100%) PDAC samples previously 
classified by Collisson et al. [25] as showing a “classical 
PDAC” GEP were shown to have GEP-A-associated 
markers; in contrast, 7/8 (89%) “quasi-mesenchymal 
PDAC” tumors as defined by Collisson et al. [25] had 
a typical GEP-B phenotype. In this series, the most 
discriminating GEP-A and GEP-B genes (higher variation 
between samples with an SD = 1) were: 1) ADAM28, 
CEACAM5, CTSE, CXCR4, EGLN3, LY75, PLAC8, 
SLC6A14, S100P, TMC5 and TMEM45B, and 2) HOXC6, 
PAPPA, SNAI2 and VGLL3, respectively (Figure 3). 
miRNAs genes which may inhibit gene expression 
in PDAC
In order to determine the impact of the miRNAs 
signature on the GEP of PDAC tumors, both the miRNA 
and mRNA gene expression data sets were combined to 
investigate potential correlations between miRNAs and 
mRNA genes which are altered in PDAC. Evaluation of 
each pair of potential miRNA-mRNA interacting genes 
identified potential interactions for 51 inversely correlated 
and 139 positively correlated (absolute value of R ≥0.7; 
p < .0001) pairs of miRNA-mRNA genes. Based on 
currently available miRNA target prediction and database 
tools, such interactions corresponded to 27 predictable 
and 1 experimentally validated (miR-30a-star/SLC7A6) 
interactions for the negatively correlated miRNA-mRNA 
pairs (Table 4). Of note, both the experimentally validated 
pair of mRNA/miRNA genes and other 4 predicted 
miRNA-mRNA interactions (miR-130b-star/TSHZ3, miR-
148a/BBS7, miR-148a/LIMA1 and miR-30a/PLAUR) 
were systematically altered in the 27 PDAC samples 
Figure 3: Biplot analysis of 27 PDAC tumors from an independent external validation dataset [25] evaluated for the 
expression of GEP-A and GEP-B overexpressed tumor markers identified in our series. PDAC samples previously classified 
by Collisson et al. as “classical PDAC” tumors (grey dots) were mostly represented by the expression of GEP-A associated genes (red 
vectors) while “quasi-mesenchymal PDAC” tumors (light blue dots) were grouped by the expression of GEP-B associated markers (purple 
vectors).
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analyzed; in turn, another 10 predicted miRNA-mRNA 
pairs were specifically altered in GEP-A cases (miR-
148a stem loop transcript/ACSL5, CTSE, SLC44A4, 
TNFRSF21 or TSPAN15, and miR-23a/COQ10A) or in 
GEP-B tumors (miR-1180/BMPER, miR-1244/C10orf118, 
miR-362-5p/FGD1 and the miR-423 stem loop transcript/
RSPO3).
DISCUSSION
PDAC is currently recognized as a genetically 
heterogeneous group of tumors, but limited information 
exists about the biological significance of such variability. 
In order to gain insight into the genetic heterogeneity of 
PDAC, here we analyzed for the first time, the global 
coding and non-coding GEP of a relatively large cohort 
of PDAC tumors vs. non-tumoral pancreatic tissues. 
Overall, our results showed two clearly defined subtypes 
of PDAC which shared a GEP clearly distinct from 
that of non-tumoral pancreatic tissues. Globally, this 
included increased expression of genes linked to PDAC 
cell proliferation, local invasion and metastatic capacity. 
Thus, the most top-ranked altered networks (e.g.: axonal 
guidance, inhibition of matrix metalloproteinases, 
semaphorin, epithelial adherent junction and Rho family 
of GTPases signaling pathways) are directly involved in 
cell-cell and cell-matrix adhesion, extracellular matrix 
degradation and tissue remodeling, angiogenesis, tumor 
cell migration and invasiveness [28-31]. In addition, 
cytoskeleton remodeling which is essential for cell 
movement and growth, is also altered in PDAC tumor 
cells as reflected by the alteration of axonal guidance, 
actin cytoskeleton, virus-entry via endocytosis, clathrin-
mediated endocytosis, macropinocytosis signaling, as 
well as signaling pathways activated by the Rho family of 
GTPases [28-30, 32]; of note, many of such processes had 
been previously described to be altered in PDAC [27, 29, 
30, 33]. PDAC tumors also showed a significant alteration 
of the early steps of cellular immune responses; this is 
possibly due to a host response against the tumor[34], 
as reflected by the alteration of cell adhesion, diapedesis 
and extravasation, IL8 signaling and antigen presentation 
via macropinocytosis signaling [35]. However, since the 
tumors here analyzed represented relatively advanced 
stages of the disease, alteration of such pathways could 
also be due to inflammation-mediated cell migration 
mechanisms [36]. Altogether, these processes found to 
be altered in PDAC encompass a pro-tumoral scenario; 
in such scenario PDAC tumor cells secrete factors that 
actively enhance recruitment of immune cells, while 
activated immune cells, produce cytokines and growth 
factors that may exert a direct effect on the tumor cells and 
the stroma [37]. This hypothesis was fully supported by 
the observation of areas containing significant leucocyte 
infiltrates in the tumoral vs. non-tumoral pancreatic 
tissues, through immunostainings for CD45 and CD15 of 
formalin-fixed, paraffin-embedded tissues from the same 
cases (data not shown). 
Interestingly, in addition to the common GEP, the 
two subgroups of PDAC here identified also showed 
clearly different GEPs. Thus, enrichment in genes 
involved in the innate and adaptative immune response 
was predominantly detected in GEP-A vs. GEP-B 
cases, even when both subgroups of tumors presented 
similar levels of infiltration by inflammatory cells (data 
not shown). These findings, together with the increased 
expression of genes correlated to immune and chronic 
pancreatic diseases, cellular stress and injury conditions, 
among GEP-A vs. GEP-B cases, point out the potential 
involvement of immune selection mechanisms (e.g.: 
selection of non-immunogenic tumor-cell variants) in 
the former subgroup of PDAC[30]. Additionally, GEP-A 
tumors also showed an altered expression of genes 
involved in cell proliferation, angiogenesis, cell motility, 
invasion and tumor progression (e.g. genes involved in the 
MSP-RON, actin nucleation by the AR-WASP complex 
and by the Rho, Rac, PAK, Cdc42, integrin, ERK/MAPK, 
Paxilin, FAK, NF-KB, calpain protease and glioma tumor 
invasiveness pathways [28, 38-48], among other genes 
[31, 49, 50]), would confer a highly-aggressive phenotype 
to GEP-A tumor cells. Of note, GEP-A tumors retained 
an epithelial GEP phenotype which includes an increased 
expression of epithelial markers, carcinoembrionary 
antigens (CEACAM1, CEACAM6 and CEACAM 5) and 
cytokeratins (KRT7 and KRT19).
In contrast to GEP-A tumors, GEP-B PDAC 
cases showed fewer specifically altered canonical 
pathways, despite an overall similar number of altered 
genes was found in both subgroups of tumors (1,183 
vs. 1,012 altered genes in GEP-A vs. GEP-B cases, 
respectively). Of note, GEP-B cases showed no specific 
GEPs associated to tumor cell proliferation; moreover, 
they had decreased expression of genes linked to 
canonical pathways associated with immune responses. 
Thus, GEP-B tumors had: i) enhanced self-defense 
mechanisms against complement-dependent cytotoxicity, 
as reflected by overexpression of the KIT mast cell-
associated molecule[51]; ii) defective expression of major 
histocompatibility complex (MHC) molecules which are 
that frequently involved in tumor immune escape [52], 
and/or; iii) greater cancer-driven immunosuppression as a 
consequence of increased expression of the programmed 
cell death 1 ligand 2 (PDCD1LG2) [53] and the VGFC[51] 
genes. Most interestingly, our results indicate activation 
of epithelial-mesenchymal transition (EMT) genes in 
GEP-B tumors as depicted by their higher expression of 
mesenchymal signature genes (e.g: CDH2, SNAI1, SNAI2 
and VIM) and other EMT-related genes (e.g. S100A4), 
together with decreased expression of epithelial markers 
(e.g: CEACAM6, EPCAM, CDH1, KRT8 and KRT18) 
[54-56], which activate the integrin linked kinase (ILK) 
signaling pathway [57], inhibit genes involved in cell-cell 
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junction signaling pathways and expression of adhesion 
molecules (e.g: DSG2, DSC2 and PKP2 genes) [58]. 
Altogether, these results suggest that in GEP-B tumors, 
immunosuppression linked to an EMT phenotype could 
be involved in the pathogenesis of PDAC. Whether 
immunosuppression precedes or develops after acquisition 
of an EMT phenotype, remains to be determined. 
Overall, the above results confirm and extend on 
previous observations about the existence of distinct 
molecular subgroups of PDAC tumors as identified by 
GEP, including a “classical epithelial” and a “quiasi-
mesenchymal” subtype of PDAC[25]. However, despite 
this, we failed to detect a third subtype of PDAC tumors 
with an exocrine-like phenotype, as previously described 
by Collisson et al. in a larger patient cohort [25]. Such 
apparently discrepant results could potentially be due 
to differences in the size of the cohort analyzed (27 
tumoral samples in our study vs. 63 PDAC samples in 
the series of Collisson et al.), the methodology used (e.g. 
macrodissected freshly-frozen PDAC tissues vs. a mixture 
of formalin-fixed paraffin-embedded and freshly-frozen 
PDAC tissues, with or without microdissection), and/or 
the comparison against non-pancreatic reference tissues 
done in our series, but not in the study by Collisson et 
al. [25]. Of note, we also failed to confirm the previously 
reported association between specific GEP and the clinical 
and histopathological features of the disease (e.g.: the 
association between a mesenchymal phenotypes and both 
adverse tumor features and a poorer prognosis) [25, 56, 
59]. Independently of the pathogenic significance of the 
distinct GEP and tumor phenotypes here described, the 
understanding of such biological pathways may contribute 
to better identify more efficient treatment strategies and 
to e.g. avoid standard PDAC therapy with gemcitabine 
and 5-fluorouracil in patients with GEP-B, due to the high 
chemoresistance of PDAC cells with an EMT phenotype 
to these treatments [56, 60].
Despite all the above, a major concern remains 
regarding the functional effect of microRNA expression 
levels on the mRNA transcript expression. Here we 
identified several miRNAs to be significantly correlated 
with expression of specific genes at the mRNA level. 
Among other miRNA-mRNA pairs, the miR-30a-star 
emerged in our series, as significantly correlated with 
an increased expression of the SLC7A6 gene transcript. 
The SLC7A6 (solute carrier 7 member of this family of 
genes) has known functions in the transport of leucin, 
being involved in promoting cell growth in many cancers 
[61, 62] and podocyte development[63]. Furthermore, 
expression of the miR-30 family of miRNAs is a key 
element during embryonic pancreatic development to 
maintain the epithelial phenotype of pancreatic tissues 
[64], their inhibition mediating an EMT phenotype in 
several types of cancer [65, 66]. Although, we were not 
able to detect any other (validated) inverse correlation for 
other miR-30 elements-genes, decreased expression of 
miR-30a, miR-30c and miR-30d was found in both GEP-A 
and GEP-B tumors with an epithelial vs. EMT phenotype, 
respectively; these results suggest that the EMT phenotype 
is potentially promoted in all PDAC tumors, but only those 
tumors carrying additional molecular/genomic alterations 
associated with immunosuppression and/or activation of 
ILK signaling could more clearly acquire a mesenchymal 
phenotype. Other miRNAs found to be altered in PDAC 
were exclusively deregulated among GEP-A or GEP-B 
tumors. Interestingly deregulated miRNA genes in GEP-A 
tumors included the stem loop transcript of miR-148a. 
The miR-148a miRNA possibly mediates overexpression 
of genes involved in tumor cell growth (e.g. acetyl-
CoA sintetase, ACSL5), migration (e.g. the TSPAN15 
tetraspanin) with an effect also on both apoptosis and 
immune responses (e.g. the TNFRSF21 tumor necrosis 
factor receptor); in turn miR-23a inhibits the antioxidative 
effect of the coenzyme Q10 homologe A (COQ10A) gene. 
In contrast, those miRNA genes which were overexpressed 
in GEP-B tumors included the miR-1180, miR-362-5p and 
the miR-423, all of which promote tumor cell proliferation 
and invasion through e.g. the BMP binding endothelial 
regulator (BMPER), the FYVE Rho GEF and PH domain 
containing 1 (FGD1) and the R-spondin 3 (RSPO3) genes. 
Interestingly, clear cut discrimination between 
GEP-A and GEP-B tumors carrying an epithelial vs. 
mesenchymal-like molecular profile could be obtained via 
a set of 63 and 97 mRNA genes overexpressed in GEP-A 
and GEP-B tumors, respectively, as also confirmed in an 
external series of 27 PDAC patients [25]. These results 
indicate that these gene signatures could potentially serve 
in the future as prior knowledge for the discovery of 
biomarker candidates (i.e: CEACAM5, GPX2, MUC13, 
S100P and TMEM45B for GEP-A cases, and PAPPA and 
VGLL3 for GEP-B tumors) that may contribute to more 
efficient treatment and/or monitoring of both subtypes of 
PDAC tumors. In addition, in our series a small panel of 
5 overexpressed PDAC markers (S100A11, GPR137B, 
SULF1, POSTN and miR-155) would allow precise 
distinction between PDAC and non-tumoral pancreatic 
tissues. In line with this hypothesis, strong expression 
of the S100A11 and GPR137B genes has been reported 
at the protein level in PDAC tissues, while SULF1 and 
POSTN are expressed at more variable patterns [67-
69]; of note all four proteins have been also found to be 
secreted and present in both tumor tissues and the plasma 
[67, 68, 70] from PDAC patients. Altogether, secretion 
of these proteins outside the tumor cell, supports the 
potential utility of these genes as candidate markers for 
the diagnosis and monitoring of PDAC patients.
In summary, the present study provides evidence for 
a common GEP of tumor cells in PDAC, at the same time 
it confirms the genetic complexity and heterogeneity of 
these tumors with at least two clearly distinct and unique 
GEPs (e.g. epithelial-like vs. mesenchymal-like genomic 
profiles), potentially reflecting different pathways involved 
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in the oncogenesis and progression of PDAC. In addition, 
our results also highlight the potential role of the tumor 
microenvironment, particularly of the immune system, 
in PDAC, with potential diagnostic and therapeutic 
implications.
MATERIALS AND METHODS
Patients and samples
Tumor tissue specimens were obtained at diagnostic 
surgery from 27 consecutive sporadic PDAC patients (18 
males and 9 females; mean age of 67 years, ranging from 
41 to 79 years); in addition, non-tumoral pancreatic tissue 
specimens were also collected from another 5 patients each 
having a different pancreatic disease (pancreatic fibrosis 
with inflammation, chronic pancreatitis, an ampullary 
tumor, a neuroendocrine tumor and a PDAC, respectively). 
All PDAC patients underwent surgical tumor resection at 
the Division of Hepatobiliary and Pancreatic Surgery of 
the University Hospital of Salamanca (Salamanca, Spain). 
PDAC tumors were diagnosed and classified according to 
Adsay et al. [71] with the following distribution: 8 cases 
corresponded to well-differentiated/grade I tumors; 11 
to moderately-differentiated/grade II, and; 8 to poorly-
differentiated/grade III PDAC. Histopathological grade 
was confirmed in all cases in a second independent 
evaluation by an experienced pathologist. Most tumors 
(21/27, 78%) were localized in the head of the pancreas, 
while the remaining six cases were localized in the 
pancreatic body (1/27, 4%), the tail (3/27, 11%) and 
the pancreatic body/tail (2/27, 7%). Mean tumor size 
at diagnostic surgery was of 3.0±0.82 cm, 6 cases 
corresponding to TNM stage IIA tumors and 21 to TNM 
stage IIB. The most relevant clinical and laboratory patient 
characteristics are summarized in Supplementary Table 1. 
Pancreatic tissue samples were collected 
immediately after surgical resection, snap frozen and 
stored in OCT at -80°C (Tumor Biobank of the University 
Hospital of Salamanca, Red de Bancos de Tumores 
de Castilla y León, Salamanca, Spain). The study was 
approved by the local ethics committee of the University 
Hospital of Salamanca (Salamanca, Spain) and informed 
consent was given by each individual prior to entering the 
study, according to the Declaration of Helsinki. Once the 
histopathological diagnosis had been established, sections 
from the paraffin-embedded tissue samples were cut from 
three different areas representative of the tumoral tissue 
with > 70% tumor cell infiltration by hematoxylin-eosin 
staining, excluding stroma-enriched tumor areas. Selection 
of the neighbour areas of the tumor containing ≥70% 
tumor cells was performed on dissected samples stored 
in OCT.
RNA extraction and gene expression profiling 
(GEP) microarray studies
For GEP, sample preparation was performed 
as described in the Affymetrix GeneChip Expression 
Analysis Manual (Santa Clara, CA, USA). Briefly, 
each frozen tissue (≥0.3 g) was crushed to powder at 
cryogenic temperatures and homogeneized in Trizol 
(Life Technologies, Inc., Rockville, MD). Total RNA was 
then extracted using the miRNeasy mini kit according 
to the manufacturer’s protocol (Qiagen, Valencia, CA); 
subsequently, the quality and integrity of the RNA was 
evaluated in an Agilent 2100 Bioanalyzer (Agilent 
Technologies Inc., Santa Clara, CA, USA). Total RNA 
(100-1,000ng) from both tumoral and non-tumoral 
pancreatic tissues was hybridized to both the Affymetrix 
Human Gene ST 1.0 Expression and the microRNA 2.0 
Expression arrays, according to the instructions of the 
manufacturer. Fluorescence signals were detected using 
the GeneChip Scanner 3000 7G (Affymetrix) and data 
stored as .CEL files.
For data analysis, GEP raw data derived from the 
Affymetrix Human Gene Expression ST 1.0 microarray 
and the microRNA 2.0 microarray, was normalized with 
the Robust Multi-array Average (RMA) algorithm; this 
included sequentially background correction, intra- 
and inter-microarray well normalization, probe set 
summarization and calculation of expression signals, 
respectively[72]. Unsupervised classification of samples 
and genes -28,869 mRNA and 4,544 human small non-
coding RNA transcripts- was performed by principal 
component (PCA) and hierarchical clustering analyses 
(HCA) using the expression signal detected for each gene 
for each probe set, and the MultiExperiment Viewer (MeV, 
version 4.8.1) [73] and Cluster 3.0 software programs 
(PAM software; http://www-stat.stanford.edu/~tibs/
PAM). Clustering was run using an Euclidean correlation 
metric and the average linkage method. For visualization 
of dendograms, the TreeView software (version 1.0.4)
[74] was used. Differentially expressed genes between 
all tumor samples or GEP-defined subgroups of PDAC 
samples vs. non-tumoral samples were identified by 
supervised two-class unpaired Significance Analysis of 
Microarray (SAM; MeV software) [75] based on a false 
discovery rate (FDR) cut off of < .0001 and an absolute 
fold change cutoff of ≥2.0.
In order to identify the best combination of genes for 
the discrimination between the GEP of PDAC tumors and 
non-neoplastic pancreatic tissues, a two-step strategy was 
used. In the first step, five prediction algorithms were used: 
1) PAM (PAM software v 2.1; University of Stanford, CA) 
[76], 2) Partial Least Squares algorithms (PLS; SIMFIT 
software v.6.9.9; www.simfit.org.uk), 3) Support Vector 
Machines (SVM), 4) K-Nearest Neigbour (KNN) and, 5) 
Random Forest algorithms; the latter three algorithms are 
implemented in the Babelomics suite (http://babelomics.
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bioinfo.cipf.es/) [77]. For this purpose, GEP data from 
two-thirds of the tumoral samples was randomly selected 
as a training dataset, while the remaining were used to 
build the validation dataset. In this first step, informative 
genes were defined as those represented in ≥ 4/5 analyses. 
In the second step, the discriminative power of each 
informative gene was assessed by receiver operating 
curve (ROC) analysis (SPSS 15.0 Inc, Chicago, IL, USA). 
Finally, those genes which depicted a high predictive 
power -area under the curve (AUC) ≥0.96- together with 
an expression fold change (vs. non-tumoral tissues) > 
4, were selected. Validation of genes was performed in 
the same pancreatic sample series (27 tumoral plus 5 
pancreatic non-tumoral samples) applying the PAM and 
SVM models, using a 10-fold and a leave-one-out-cross 
validation method, respectively. 
For the identification of miRNA candidates 
acting as gene-regulators in PDAC samples, Spearman 
correlation analyses were performed to identify significant 
correlations between individual miRNA and mRNA gene 
transcripts across tumoral (n = 27) and non-tumoral (n = 
5) samples. Each miRNA-mRNA interaction identified 
was subsequently evaluated with the Ingenuity Pathway 
Analysis software (IPA, Ingenuity Systems, www.
ingenuity.com), as well as with available databases of 
experimentally validated miRNA interactions (TarBase 
6.0 and miRWalk-database) and miRNA target prediction 
tools (DIANA-microT-CDS v5.0, miRWalk-database 
and miRecords) [78, 79]. Functional enrichment analysis 
of deregulated genes, analysis of canonical pathways, 
correlation networks, as well as gene-gene and gene-
miRNA interactions were defined using the IPA software. 
Validation of gene expression profiles by 
quantitative real-time PCR assays
TaqMan Gene Expression Assays were used to 
validate GEP in the same samples used for microarray 
studies via the Step One Plus Real-Time PCR System 
-Applied Biosystems (ABI; Foster City, CA, USA) 
according to the manufacturer’s instructions. The assays ID 
for the genes studied were as follows: Hs_00429010_m1 
(PDIA2), Hs_00170815_m1 (POSTN), Hs_00418420_m1 
(SCYN), 002220 (hsa-miR-216a), 002337 (hsa-miR-217), 
002623 (hsa-miR-155) and 000507 (hsa-miR-203). Each 
PCR was carried out in duplicate in a final volume of 10 
uL using the TaqMan Fast Universal Mastermix (ABI) and 
the following cycling parameters: incubation at 95ºC (20 
s), followed by 50 cycles at 95ºC (1s) and an incubation 
at 60ºC (20s). GEP and miRNA expression data was 
normalized against the GAPDH internal housekeeping 
gene and the RNU43 internal control, and it was further 
analyzed using the StepOne software (v2.0; ABI). The 
relative amounts of the quantified genes were calculated 
using the following equation: 2-ΔCT (ΔC
T
 = C
T 
GENE-C
T 
GAPDH or RNU43) expressed as arbitrary units (AU); 
results showed a high degree of correlation between data 
from both microarrays and RQ-PCR methods, for all genes 
evaluated (r2≥ 0.66, p < .0001; Supplementary Figure 1).
External validation series of PDAC tumors
External validation of the predictive value of 
the differentially expressed genes that discriminated 
between the distinct GEP-defined subgroups of PDAC 
tumors found in our series, was performed in a group 
of previously reported PDAC patients (n = 27). GEP 
array data files (Affymetrix Human Genome U133 Plus 
2.0 Array) are publicly available at the GEO database 
(accession number GSE17891) [25]. Downloaded data 
CEL files were normalized using the RMA algorithm and 
overlapping probe sets were defined on the basis of probe 
specificity, using the GATExplorer server[80]. Probe sets 
with the best specificity to the interrogated genes (see 
Supplementary Table 7) were selected, and the expression 
signals detected for each gene for each probe set were 
further analyzed using the column metric preserving biplot 
assay[81] implemented in the SIMFIT statistical software 
(http://www.simfit.org.uk/).
Other statistical methods
The Mann-Whitney U test and a linear regression 
model were used to evaluate the statistical significance 
of differences observed between groups and to explore 
the degree of correlation between different variables, 
respectively (SPSS 15.0 Inc.). P-values ≤.05 were 
considered to be associated with statistical significance.
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